UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biowaiver Approach for Biopharmaceutics Classification System Class 3 Compound Metformin Hydrochloride Using In Silico Modeling

Journal of pharmaceutical sciences, 2012-05, Vol.101 (5), p.1773-1782

2012

Volltextzugriff (PDF)

Simultaneous oral therapeutic and intravenous 14C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

British journal of clinical pharmacology, 2013-03, Vol.75 (3), p.763-768

2013

Volltextzugriff (PDF)

Pharmacokinetics of Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus: a Phase I Study

Antimicrobial Agents and Chemotherapy, 1999-05, Vol.43 (5), p.1230-1233

1999

Volltextzugriff (PDF)

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

AIDS (London), 2007-06, Vol.21 (10), p.1293-1299

2007

Volltextzugriff (PDF)

Single-dose pharmacokinetics of rifapentine in elderly men

Pharmaceutical research, 1998-08, Vol.15 (8), p.1286-1291

1998

Volltextzugriff (PDF)

Pharmacokinetics of Rifapentine in Patients with Varying Degrees of Hepatic Dysfunction

Journal of clinical pharmacology, 1998-06, Vol.38 (6), p.517-524

1998

Volltextzugriff (PDF)

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS

Bioanalysis, 2012-08, Vol.4 (15), p.1855-1870

2012

Volltextzugriff (PDF)

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

Antimicrobial Agents and Chemotherapy, 1997-12, Vol.41 (12), p.2670-2679

1997

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)

Journal of acquired immune deficiency syndromes (1999), 2010-04, Vol.53 (5), p.598-605

2010

Volltextzugriff (PDF)

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole

Clinical pharmacokinetics, 2002, Vol.41 Suppl 1 (Supplement 1), p.37-44

2002

Volltextzugriff (PDF)

Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable

Journal of acquired immune deficiency syndromes (1999), 2010-01, Vol.53 (1), p.78-85

2010

Volltextzugriff (PDF)

Single-dose pharmacokinetics of rifapentine in women

Journal of pharmacokinetics and biopharmaceutics, 1998-02, Vol.26 (1), p.75-85

1998

Volltextzugriff (PDF)

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

Journal of clinical oncology, 1993-11, Vol.11 (11), p.2127-2135

1993

Volltextzugriff (PDF)

PHARMACOKINETICS AND SAFETY OF SINGLE INTRAVENOUS AND ORAL DOSES OF DOLASETRON MESYLATE IN HEALTHY WOMEN

Biopharmaceutics & drug disposition, 1997-05, Vol.18 (4), p.361-369

1997

Volltextzugriff (PDF)

Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties

Retrovirology, 2005-12, Vol.2 (S1), p.S12-S12, Article S12

2005

Volltextzugriff (PDF)

Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro

Retrovirology, 2005-12, Vol.2 (S1), p.P158-P158, Article P158

2005

Volltextzugriff (PDF)

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole: Desloratadine: Clinical Pharmacokinetics of a Novel H1 Receptor Antagonist

Clinical pharmacokinetics, 2002, Vol.41, p.37-44

2002

Volltextzugriff (PDF)

Single and multiple dose pharmacokinetics of rifapentine in man: part II

The international journal of tuberculosis and lung disease, 1999-05, Vol.3 (5), p.437

1999

Volltextzugriff (PDF)

Simultaneous oral therapeutic and intravenous 14 C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

British journal of clinical pharmacology, 2013-03, Vol.75 (3), p.763-768

2013

Volltextzugriff (PDF)

Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I

The international journal of tuberculosis and lung disease, 1999-05, Vol.3 (5), p.426

1999

Volltextzugriff (PDF)

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children

Clinical pharmacology and therapeutics, 1996-11, Vol.60 (5), p.485-492

1996

Volltextzugriff (PDF)

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects

Cancer chemotherapy and pharmacology, 1999, Vol.43 (2), p.126-132

1999

Volltextzugriff (PDF)

The effect of food on the bioavailability of dolasetron mesylate tablets

Biopharmaceutics & drug disposition, 1998-01, Vol.19 (1), p.17-19

1998

Volltextzugriff (PDF)

Prediction of bone penetration and efficacies of five fluoroquinolone antibiotics in the treatment of pseudomonal chronic osteomyelitis using a rat model

Keung, Anther Chi Fung

1991

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Adult
(15)
Male
(15)
Pharmacology. Drug Treatments
(15)
Pharmacology & Pharmacy
(12)
Middle Aged
(11)
Female
(10)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(8)
Area Under Curve
(8)
Cross-Over Studies
(8)
Rifampin - Pharmacokinetics
(8)
Antibacterial Agents
(7)
Administration, Oral
(6)
Antitubercular Agents - Pharmacokinetics
(6)
Pharmacokinetics
(6)
Rifampin - Analogs & Derivatives
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Biowaiver Approach for Biopharmaceutics Classification System Class 3 Compound Metformin Hydrochloride Using In Silico Modeling

Simultaneous oral therapeutic and intravenous 14C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

Pharmacokinetics of Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus: a Phase I Study

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

Single-dose pharmacokinetics of rifapentine in elderly men

Pharmacokinetics of Rifapentine in Patients with Varying Degrees of Hepatic Dysfunction

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole

Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable

Single-dose pharmacokinetics of rifapentine in women

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

PHARMACOKINETICS AND SAFETY OF SINGLE INTRAVENOUS AND ORAL DOSES OF DOLASETRON MESYLATE IN HEALTHY WOMEN

Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties

Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole: Desloratadine: Clinical Pharmacokinetics of a Novel H1 Receptor Antagonist

Single and multiple dose pharmacokinetics of rifapentine in man: part II

Simultaneous oral therapeutic and intravenous 14 C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects

The effect of food on the bioavailability of dolasetron mesylate tablets

Prediction of bone penetration and efficacies of five fluoroquinolone antibiotics in the treatment of pseudomonal chronic osteomyelitis using a rat model

Suchergebnisse filtern